In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates

  • S. G
  • L. B
  • N. B
 et al. 
  • 2

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

We present a unified quantitative approach to predict the in vivo alteration in drug exposure caused by either cytochrome P450 (CYP) gene polymorphisms or CYP-mediated drug-drug interactions (DDI). An application to drugs metabolized by CYP2C19 is presented. The metrics used is the ratio of altered drug area under the curve (AUC) to the AUC in extensive metabolizers with no mutation or no interaction. Data from 42 pharmacokinetic studies performed in CYP2C19 genetic subgroups and 18 DDI studies were used to estimate model parameters and predicted AUC ratios by using Bayesian approach. Pharmacogenetic information was used to estimate a parameter of the model which was then used to predict DDI. The method adequately predicted the AUC ratios published in the literature, with mean errors of -0.15 and -0.62 and mean absolute errors of 0.62 and 1.05 for genotype and DDI data, respectively. The approach provides quantitative prediction of the effect of five genotype variants and 10 inhibitors on the exposure to 25 CYP2C19 substrates, including a number of unobserved cases. A quantitative approach for predicting the effect of gene polymorphisms and drug interactions on drug exposure has been successfully applied for CYP2C19 substrates. This study shows that pharmacogenetic information can be used to predict DDI. This may have important implications for the development of personalized medicine and drug development. © 2013 American Association of Pharmaceutical Scientists.

Author-supplied keywords

  • *DNA polymorphism
  • *cyp2c19 gene
  • *cytochrome P450 2C19/ec [Endogenous Compound]
  • *enzyme substrate
  • *pharmacogenetics
  • Bayes theorem
  • allele
  • amitriptyline/pk [Pharmacokinetics]
  • amitriptyline/po [Oral Drug Administration]
  • area under the curve
  • article
  • cilostazol/pk [Pharmacokinetics]
  • cilostazol/po [Oral Drug Administration]
  • citalopram/pk [Pharmacokinetics]
  • citalopram/po [Oral Drug Administration]
  • clomipramine/pk [Pharmacokinetics]
  • clomipramine/po [Oral Drug Administration]
  • clopidogrel/pk [Pharmacokinetics]
  • clopidogrel/po [Oral Drug Administration]
  • controlled study
  • diazepam/pk [Pharmacokinetics]
  • diazepam/po [Oral Drug Administration]
  • drug activity
  • drug clearance
  • drug exposure
  • drug metabolism
  • drug potency
  • drug potentiation
  • enzyme substrate complex
  • error
  • escitalopram/pk [Pharmacokinetics]
  • escitalopram/po [Oral Drug Administration]
  • fluconazole/cb [Drug Combination]
  • fluconazole/pd [Pharmacology]
  • fluconazole/pk [Pharmacokinetics]
  • fluoxetine/pk [Pharmacokinetics]
  • fluoxetine/po [Oral Drug Administration]
  • fluvoxamine/cb [Drug Combination]
  • fluvoxamine/pd [Pharmacology]
  • fluvoxamine/pk [Pharmacokinetics]
  • genotype
  • gliclazide/pk [Pharmacokinetics]
  • gliclazide/po [Oral Drug Administration]
  • homozygosity
  • human
  • in vivo study
  • lansoprazole/cb [Drug Combination]
  • lansoprazole/pk [Pharmacokinetics]
  • lansoprazole/po [Oral Drug Administration]
  • methylphenobarbital/pk [Pharmacokinetics]
  • methylphenobarbital/po [Oral Drug Administration]
  • moclobemide/pk [Pharmacokinetics]
  • moclobemide/po [Oral Drug Administration]
  • nelfinavir/pk [Pharmacokinetics]
  • nelfinavir/po [Oral Drug Administration]
  • omeprazole/cb [Drug Combination]
  • omeprazole/pd [Pharmacology]
  • omeprazole/pk [Pharmacokinetics]
  • omeprazole/po [Oral Drug Administration]
  • pantoprazole/pd [Pharmacology]
  • pantoprazole/pk [Pharmacokinetics]
  • pantoprazole/po [Oral Drug Administration]
  • praziquantel/pk [Pharmacokinetics]
  • praziquantel/po [Oral Drug Administration]
  • prediction
  • proguanil/pk [Pharmacokinetics]
  • proguanil/po [Oral Drug Administration]
  • proton pump inhibitor/pk [Pharmacokinetics]
  • quantitative analysis
  • rabeprazole/pk [Pharmacokinetics]
  • rabeprazole/po [Oral Drug Administration]
  • sertraline/pk [Pharmacokinetics]
  • sertraline/po [Oral Drug Administration]
  • sibutramine/pk [Pharmacokinetics]
  • sibutramine/po [Oral Drug Administration]
  • trimipramine/pk [Pharmacokinetics]
  • trimipramine/po [Oral Drug Administration]
  • voriconazole/pd [Pharmacology]
  • voriconazole/pk [Pharmacokinetics]
  • voriconazole/po [Oral Drug Administration]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Goutelle S.

  • Bourguignon L.

  • Bleyzac N.

  • Berry J.

  • Clavel-Grabit F.

  • Tod M.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free